Publications (246)

2023

  1. Counterintuitive structural and functional effects due to naturally occurring mutations targeting the active site of the disease-associated NQO1 enzyme*

    FEBS Journal, Vol. 290, Núm. 7, pp. 1855-1873

  2. Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium

    Kidney International Reports, Vol. 8, Núm. 10, pp. 2029-2042

  3. Postcolonoscopy colorectal cancer: Prevalence, categorization and root-cause analysis based on the World Endoscopic Organization system

    Gastroenterologia y Hepatologia

  4. Thyroid Fine Needle Aspiration, the Bethesda System, and the BRAFV600EMutation in Papillary Thyroid Carcinoma: Association and Prediction for Biopsy

    Acta Cytologica, Vol. 67, Núm. 4, pp. 346-356

2022

  1. Allosteric Communication in the Multifunctional and Redox NQO1 Protein Studied by Cavity‐Making Mutations

    Antioxidants, Vol. 11, Núm. 6

  2. Atypical spindle cell lipomatous tumour presenting as a large retroperitoneal mass – a case report and review of the literature

    Polish Journal of Pathology, Vol. 73, Núm. 4, pp. 364-370

  3. Different phenotypic outcome due to site-specific phosphorylation in the cancer-associated NQO1 enzyme studied by phosphomimetic mutations

    Archives of Biochemistry and Biophysics, Vol. 729

  4. Effect of naturally-occurring mutations on the stability and function of cancer-associated NQO1: Comparison of experiments and computation

    Frontiers in Molecular Biosciences, Vol. 9

  5. Gastric metastases with a choriocarcinoma component from a postpuberal teratoma with mature histology

    Revista Espanola de Patologia, Vol. 55, pp. S49-S53

  6. Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry

    Kidney International Reports, Vol. 7, Núm. 7, pp. 1608-1618

  7. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

    Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146

  8. Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias

    Bioorganic Chemistry, Vol. 129

  9. Molecular diagnosis in non-small-cell lung cancer: Expert opinion on ALK and ROS1 testing

    Journal of Clinical Pathology, Vol. 75, Núm. 3, pp. 145-153

  10. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production

    European Journal of Medicinal Chemistry, Vol. 237

  11. Phosphorylation of Thr9 Affects the Folding Landscape of the N-Terminal Segment of Human AGT Enhancing Protein Aggregation of Disease-Causing Mutants

    Molecules (Basel, Switzerland), Vol. 27, Núm. 24

  12. Re: Epigenomic and Transcriptional Profiling Identifies Impaired Glyoxylate Detoxification in NAFLD as a Risk Factor for Hyperoxaluria

    Journal of Urology

  13. Targeting HIF-1α Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1

    Journal of Personalized Medicine, Vol. 12, Núm. 5

  14. Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

    BMC Nephrology, Vol. 23, Núm. 1

2021

  1. ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer

    Oncogene, Vol. 40, Núm. 16, pp. 2923-2935

  2. Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria

    Cell Reports, Vol. 36, Núm. 8